Iovance Biotherapeutics, Inc.
IOVA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$14.09
KIRA · Stoqly’s AI analyst, in plain words
- Iovance Biotherapeutics, Inc. had $264M of revenue in fiscal 2025, up 60.6% on the year before.
- Its operating margin was −153.1%, up 87.8 pts: of every 100 in sales, about −153 is left after running the business.
- Iovance Biotherapeutics, Inc. lost $391M in fiscal 2025.
- Free cash flow was −$336M in fiscal 2025, −127.6% of revenue.
Market cap
$6.3M
P/E
—
Revenue
$264M
Net income
−$391M
Free cash flow
−$336M
Operating margin
−153.1%
Iovance Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+60.6%
Yes. Sales grew 60.6% last year.
Does it make a profit?
−148.4%
No. It lost money last year.
Does profit turn into cash?
−127.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Iovance Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- IOVANCE BIOTHERAPEUTICS, INC.
- CIK
- 0001425205
Iovance Biotherapeutics, Inc. · IOVA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $1.2M | $164M | $264M |
| Revenue growth | — | — | — | 13,699.0% | 60.6% |
| Gross margin | — | — | 13.1% | 43.2% | 34.3% |
| Operating margin | — | — | −38,735.0% | −240.9% | −153.1% |
| Net income | −$342M | −$396M | −$444M | −$372M | −$391M |
| Net margin | — | — | −37,345.4% | −226.8% | −148.4% |
| Diluted EPS | −$2.23 | −$2.49 | −$1.89 | −$1.28 | −$1.09 |
| Cash | |||||
| Cash from operations | −$228M | −$293M | −$362M | −$353M | −$302M |
| Capital expenditure | $37.6M | $20.4M | $22.3M | $11.1M | $33.8M |
| Free cash flow | −$266M | −$313M | −$384M | −$364M | −$336M |
| FCF margin | — | — | −32,305.3% | −221.9% | −127.6% |
| Share count change | 10.9% | 3.8% | 47.6% | 23.3% | 23.2% |
| Debt and strength | |||||
| Cash and short-term investments | $504M | $472M | $280M | $324M | $297M |
| Shareholders' equity | $622M | $500M | $585M | $710M | $699M |
| Current ratio | 5.7x | 5.2x | 2.8x | 3.7x | 3.2x |
| Returns and quality | |||||
| Return on equity | −53.6% | −70.6% | −81.9% | −57.5% | −55.5% |
| Return on tangible equity | −55.1% | −79.2% | −125.0% | −87.0% | −93.3% |
| Piotroski F-score | — | — | — | 5 | 2 |
| Altman Z'' | −0.2 | −4.7 | −7.6 | −5.3 | −7.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Iovance Biotherapeutics, Inc. · IOVA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.09 a share, the company is worth $6.3M.
Source: SEC EDGAR XBRL filings (CIK 0001425205). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.